The find led to the development of a new class of obesity and diabetes drugs, including Ozempic
Semaglutide 2.65 mg/ml + L-carnitine 100 mg/ml is a Glucagon-like peptide receptor agonist and is an injectable prescription medicine used for adults with obesity (BMI 30) or overweight (excess weight) (BMI 27) who also have weight-related medical problems to help them lose weight and keep the weight off
The submission is supported by the SURPASS CVOT trial, which showed that Mounjaro reduced the risk of MACE including cardiovascular (CV) death, heart attack, or stroke by 8% compared with dulaglutide (Trulicity
Wegovy is FDA-approved for weight loss and, in March 2024, it became the first FDA-approved treatment to reduce the risk of major cardiovascular events in adults with overweight or obesity
$31.99 $61.99Price range: $31.99 through $61.99 $27.19 $52.69Price range: $27.19 through $52.69 $38.99 $54.99Price range: $38.99 through $54.99 $33.14 $46.74Price range: $33.14 through $46.74 $14.99 $18.99Price range: $14.99 through $18.99 $12.74 $16.14Price range: $12.74 through $16.14